文献速递头颈部肿瘤放疗

诱导化疗联合同步放化疗对比诱导化疗联合单纯容积旋转调强放疗治疗II-IVB期鼻咽癌患者的回顾性对照研究

Induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus volumetric modulated arc therapy alone in the treatment of stage II-IVB nasopharyngeal carcinoma patients: a retrospective controlled study.
PubMed 文献 · Radiat Oncol · 2018-08-13

该回顾性对照研究纳入2012年1月至2016年3月共217例II-IVB期鼻咽癌患者,其中139例接受诱导化疗后单纯容积旋转调强放疗,78例接受诱导化疗联合同步放化疗。两组5年总生存率和无进展生存率无显著差异,但同步放化疗组3-4级血液学及消化道毒性、黏膜炎和口干发生率更高。

要点

  • 诱导化疗后单纯容积旋转调强放疗与联合同步放化疗相比,5年总生存率和无进展生存率均无显著差异。
  • 同步放化疗组3-4级白细胞减少/中性粒细胞减少、胃肠道反应、黏膜炎和口干发生率显著高于单纯放疗组。
  • 多因素分析显示治疗模式(单纯放疗 vs 同步放化疗)不是总生存率或无进展生存率的独立预后因素。

核心结论

  • 在II-IVB期鼻咽癌患者中,诱导化疗后单纯容积旋转调强放疗与诱导化疗联合同步放化疗相比,总生存率和无进展生存率无显著差异,但同步放化疗组不良反应更多。

研究设计与样本

  • 回顾性对照研究,纳入2012年1月至2016年3月共217例鼻咽癌患者,其中139例接受诱导化疗后单纯容积旋转调强放疗,78例接受诱导化疗联合同步放化疗。

主要发现

  • 诱导化疗后单纯放疗组与同步放化疗组的5年总生存率分别为57.5%和47.8%,5年无进展生存率分别为41.8%和38.4%,两组生存差异均无统计学意义(均p > 0.05)。
  • 多因素分析表明治疗模式(诱导化疗后单纯放疗 vs 诱导化疗联合同步放化疗)不是总生存率或无进展生存率的独立预后因素。
  • 同步放化疗组较单纯放疗组3-4级白细胞减少/中性粒细胞减少发生率更高(20.51% vs 3.60%,p < 0.001)。
  • 同步放化疗组较单纯放疗组胃肠道反应(恶心/呕吐/腹泻)发生率更高(41.03% vs 2.16%,p < 0.001)。
  • 同步放化疗组较单纯放疗组黏膜炎发生率更高(47.44% vs 29.50%,p = 0.01),口干发生率更高(48.72% vs 34.53%,p = 0.04)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the era of intensity-modulated radiotherapy (IMRT), the role of additional concurrent chemotherapy (CC) to radiotherapy (RT) after induction chemotherapy (IC) compared to IC followed by RT alone remains unclear for stage II-IVB nasopharyngeal carcinoma (NPC) patients. The aim of this study was to evaluate the efficacy and toxicities of IC/RT and IC/CCRT in the treatment of NPC with volumetric modulated arc therapy (VMAT). METHODS: From January 2012 to March 2016, a total of 217 NPC patients were retrospectively assessed. Of the 217 patients, 139 patients received IC followed by VMAT alone and 78 patients received IC plus CCRT. Overall survival (OS), progression-free survival (PFS) and toxicities were assessed. RESULTS: The 5-year OS, PFS rates were 57.5%, 41.8% and 47.8%, 38.4% for the IC/RT and IC/CCRT arms, respectively, without significant difference in survival between the two groups (both p > 0.05). Multivariate analysis indicated that treatment modality (IC/RT vs. IC/CCRT) was not an independent prognostic factor for OS or PFS. Grade 3-4 leukopenia/neutropenia (3.60% vs. 20.51%, p < 0.001), gastrointestinal disorder (nausea/vomiting/diarrhea, 2.16% vs. 41.03%, p < 0.001), mucositis (29.50% vs. 47.44%, p = 0.01) and xerostomia (34.53% vs. 48.72%, p = 0.04) were more frequent in the IC/ CCRT arm than in the IC/RT arm during VMAT. CONCLUSIONS: No significant difference in OS and PFS was observed between IC plus VMAT alone and IC/CCRT in the treatment of stage II-IVB NPC patients, however, more side effects were observed in the IC/CCRT arm.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Liu L, Fei Z, Chen M, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus volumetric modulated arc therapy alone in the treatment of stage II-IVB nasopharyngeal carcinoma patients: a retrospective controlled study. Radiat Oncol. 2018. PMID: 30103765. doi:10.1186/s13014-018-1092-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。